Navigation Links
Jefferson researchers provide genetic evidence that antioxidants can help treat cancer
Date:2/15/2011

PHILADELPHIAResearchers from Jefferson's Kimmel Cancer Center have genetic evidence suggesting the antioxidant drugs currently used to treat lung disease, malaria and even the common cold can also help prevent and treat cancers because they fight against mitochondrial oxidative stressa culprit in driving tumor growth.

For the first time, the researchers show that loss of the tumor suppressor protein Caveolin-1 (Cav-1) induces mitochondrial oxidative stress in the stromal micro-environment, a process that fuels cancer cells in most common types of breast cancer.

"Now we have genetic proof that mitochondrial oxidative stress is important for driving tumor growth," said lead researcher Michael P. Lisanti, M.D., Ph.D., professor of cancer biology at Jefferson Medical College of Thomas Jefferson University and member of the Kimmel Cancer Center at Jefferson. "This means we need to make anti-cancer drugs that specially target this type of oxidative stress. And there are already antioxidant drugs out there on the market as dietary supplements, like N-acetyl cysteine."

These findings were published in the online February 15 issue of Cancer Biology & Therapy.

Lisanti's lab previously discovered Cav-1 as a biomarker that functions as a tumor suppressor and is the single strongest predictor of breast cancer patient outcome. For example, if a woman has triple negative breast cancer and is Cav-1 positive in the stroma, her survival is greater than 75 percent at 12 years, versus less than 10 percent at 5 years if she doesn't have the Cav-1 protein, according to Dr. Lisanti.

The researchers also established Cav-1's role in oxidative stress and tumor growth; however, where that stress originates and its mechanism(s) were unclear.

To determine this, Jefferson researchers applied a genetically tractable model for human cancer associated fibroblasts in this study using a targeted sh-RNA knock-down approach. Without the Cav-1 protein, researchers found that oxidative stress in cancer associated fibroblasts leads to mitochondrial dysfunction in stromal fibroblasts. In this context, oxidative stress and the resulting autophagy (producton of recycled nutrients) in the tumor-microenvironment function as metabolic energy or "food" to "fuel" tumor growth.

The researchers report that the loss of Cav-1 increases mitochondrial oxidative stress in the tumor stroma, increasing both tumor mass and tumor volume by four-fold, without any increase in tumor angiogenesis.

"Antioxidants have been associated with cancer reducing effectsbeta carotene, for examplebut the mechanisms, the genetic evidence, has been lacking," Dr. Lisanti said. "This study provides the necessary genetic evidence that reducing oxidative stress in the body will decrease tumor growth."

Currently, anti-cancer drugs targeting oxidative stress are not used because is it commonly thought they will reduce the effectiveness of certain chemotherapies, which increase oxidative stress.

"We are not taking advantage of the available drugs that reduce oxidative stress and autophagy, including metformin, chloroquine and N-acetyl cysteine," Dr. Lisanti said. "Now that we have genetic proof that oxidative stress and resulting autophagy are important for driving tumor growth, we should re-consider using antioxidants and autophagy inhibitors as anti-cancer agents."

The diabetic drug metformin and chloroquine, which is used for the prevention and treatment of malaria, prevent a loss of Cav-1 in cancer associated fibroblasts (which is due to oxidative stress), functionally cutting off the fuel supply to cancer cells.

This research also has important implications for understanding the pathogenesis of triple negative and tamoxifen-resistance in ER-positive breast caner patients, as well as other epithelial cancers, such as prostate cancers.

"Undoubtedly, this new genetically tractable system for cancer associated fibroblasts will help identify other key genetic 'factors' that can block tumor growth," Dr. Lisanti said.


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related biology news :

1. Jefferson researchers receive W.W. Smith Charitable Trust
2. Jefferson receives $3 million NIH grant to study molecular and genetic mechanisms in platelets
3. Jefferson scientists identify a new protein involved in longevity
4. US Department of State names UCR entomologist a Jefferson Science Fellow
5. Jefferson receives $1.7 million grant to study stem cells in intervertebral discs of the spine
6. Jefferson researcher awarded Landenberger Foundation grant for ALS research
7. Jefferson scientists discover a key protein regulator of inflammation and cell death
8. Jefferson Department of Surgery announces new pancreas tumor registry
9. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
10. Researchers working toward automating sedation in intensive care units
11. Boston University School of Medicine researchers receive NIMH brain awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/3/2017)... -- Onitor, provider of digital health technology for consumers, ... biometric data-driven program designed to aid weight loss for ... Consumer Electronics Show (CES) in Las Vegas ... World Health Organization (WHO), have identified lifestyle risks that ... overweight or obese. WHO also states that more people ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... 18, 2017 , ... Opal Kelly, a leading producer of ... announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 interface ... factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface delivers ...
(Date:1/18/2017)... 18, 2017   Boston Biomedical , an industry ... target cancer stemness pathways, will feature data from two ... the 2017 ASCO Gastrointestinal Cancers Symposium, held from January ... Napabucasin is an orally-administered investigational agent designed ... Cancer stem cells (CSCs) possess the property of ...
(Date:1/18/2017)...   Parent Project Muscular Dystrophy (PPMD) , a ... muscular dystrophy (Duchenne) , today announced a $600,000 grant ... Technology (NJIT) and Talem Technologies (Talem) as part of ... to assist people living with Duchenne. PPMD is funding ... embedded computer, software, a force sensor and a motor ...
(Date:1/18/2017)... ... 18, 2017 , ... Total Orthopedics and Sports Medicine ( ... The operation took place on Wednesday, January 11, 2017 at Long Island Jewish, ... cervical discectomy and fusion on a 42 year old female who was in ...
Breaking Biology Technology: